Peg-Intron BLA accepted for review

The FDA accepted for filing Schering-Plough's BLA for Peg-Intron, a formulation of SGP's Intron A interferon alfa-2b, to treat chronic hepatitis C infection. Peg-Intron uses polyethylene glycol techno...